The use of peripheral stem cell support of high-dose chemotherapy.

Margaret Anne Kessinger, James Olen Armitage

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Blood-derived stem cells are a functionally equivalent alternative to marrow-derived stem cells when autotransplanted to restore hematopoiesis that has been iatrogenically ablated. This alternate source of stem cells is particularly useful for patients who are candidates for marrow-ablative therapy and who also have bone marrow abnormalities that make it an unsuitable product for transplantation. When autologous blood-derived stem cells that were collected while their numbers were deliberately expanded in the circulation (mobilized) are transplanted, the resultant recovery of marrow function is very rapid. Because autologous bone marrow transplantation alone cannot result in hematopoietic recovery that is as rapid, peripheral stem cells have been preferred to bone marrow for autografting in some patients. This early recovery involves not only granulocytes but also platelets and red cells. Currently available cytokines administered at the time of ABMT usually facilitate only rapid granulocyte recovery. Emerging studies indicate that other consequential benefits of peripheral stem cell infusion that have not yet been fully recognized may exist. If, ultimately, techniques are developed that produce optimal stem cell mobilization for every eligible patient, then perhaps peripheral stem cell collections can be completed in 1 to 2 days. These cells could be used to minimize or ameliorate the hematopoietic toxicity associated with myelotoxic therapy. Perhaps then the technique eventually will become a routine adjunct to chemotherapy administration.

Original languageEnglish (US)
Pages (from-to)167-175
Number of pages9
JournalImportant advances in oncology
StatePublished - Jan 1 1993

Fingerprint

Bone Marrow
Drug Therapy
Stem Cells
Autologous Transplantation
Granulocytes
Hematopoietic Stem Cell Mobilization
Recovery of Function
Hematopoiesis
Bone Marrow Transplantation
Blood Platelets
Transplantation
Peripheral Blood Stem Cells
Cytokines
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The use of peripheral stem cell support of high-dose chemotherapy. / Kessinger, Margaret Anne; Armitage, James Olen.

In: Important advances in oncology, 01.01.1993, p. 167-175.

Research output: Contribution to journalReview article

@article{9d1d70100ddd43c0951e130b35ca1693,
title = "The use of peripheral stem cell support of high-dose chemotherapy.",
abstract = "Blood-derived stem cells are a functionally equivalent alternative to marrow-derived stem cells when autotransplanted to restore hematopoiesis that has been iatrogenically ablated. This alternate source of stem cells is particularly useful for patients who are candidates for marrow-ablative therapy and who also have bone marrow abnormalities that make it an unsuitable product for transplantation. When autologous blood-derived stem cells that were collected while their numbers were deliberately expanded in the circulation (mobilized) are transplanted, the resultant recovery of marrow function is very rapid. Because autologous bone marrow transplantation alone cannot result in hematopoietic recovery that is as rapid, peripheral stem cells have been preferred to bone marrow for autografting in some patients. This early recovery involves not only granulocytes but also platelets and red cells. Currently available cytokines administered at the time of ABMT usually facilitate only rapid granulocyte recovery. Emerging studies indicate that other consequential benefits of peripheral stem cell infusion that have not yet been fully recognized may exist. If, ultimately, techniques are developed that produce optimal stem cell mobilization for every eligible patient, then perhaps peripheral stem cell collections can be completed in 1 to 2 days. These cells could be used to minimize or ameliorate the hematopoietic toxicity associated with myelotoxic therapy. Perhaps then the technique eventually will become a routine adjunct to chemotherapy administration.",
author = "Kessinger, {Margaret Anne} and Armitage, {James Olen}",
year = "1993",
month = "1",
day = "1",
language = "English (US)",
pages = "167--175",
journal = "Important advances in oncology",
issn = "0883-5896",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - The use of peripheral stem cell support of high-dose chemotherapy.

AU - Kessinger, Margaret Anne

AU - Armitage, James Olen

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Blood-derived stem cells are a functionally equivalent alternative to marrow-derived stem cells when autotransplanted to restore hematopoiesis that has been iatrogenically ablated. This alternate source of stem cells is particularly useful for patients who are candidates for marrow-ablative therapy and who also have bone marrow abnormalities that make it an unsuitable product for transplantation. When autologous blood-derived stem cells that were collected while their numbers were deliberately expanded in the circulation (mobilized) are transplanted, the resultant recovery of marrow function is very rapid. Because autologous bone marrow transplantation alone cannot result in hematopoietic recovery that is as rapid, peripheral stem cells have been preferred to bone marrow for autografting in some patients. This early recovery involves not only granulocytes but also platelets and red cells. Currently available cytokines administered at the time of ABMT usually facilitate only rapid granulocyte recovery. Emerging studies indicate that other consequential benefits of peripheral stem cell infusion that have not yet been fully recognized may exist. If, ultimately, techniques are developed that produce optimal stem cell mobilization for every eligible patient, then perhaps peripheral stem cell collections can be completed in 1 to 2 days. These cells could be used to minimize or ameliorate the hematopoietic toxicity associated with myelotoxic therapy. Perhaps then the technique eventually will become a routine adjunct to chemotherapy administration.

AB - Blood-derived stem cells are a functionally equivalent alternative to marrow-derived stem cells when autotransplanted to restore hematopoiesis that has been iatrogenically ablated. This alternate source of stem cells is particularly useful for patients who are candidates for marrow-ablative therapy and who also have bone marrow abnormalities that make it an unsuitable product for transplantation. When autologous blood-derived stem cells that were collected while their numbers were deliberately expanded in the circulation (mobilized) are transplanted, the resultant recovery of marrow function is very rapid. Because autologous bone marrow transplantation alone cannot result in hematopoietic recovery that is as rapid, peripheral stem cells have been preferred to bone marrow for autografting in some patients. This early recovery involves not only granulocytes but also platelets and red cells. Currently available cytokines administered at the time of ABMT usually facilitate only rapid granulocyte recovery. Emerging studies indicate that other consequential benefits of peripheral stem cell infusion that have not yet been fully recognized may exist. If, ultimately, techniques are developed that produce optimal stem cell mobilization for every eligible patient, then perhaps peripheral stem cell collections can be completed in 1 to 2 days. These cells could be used to minimize or ameliorate the hematopoietic toxicity associated with myelotoxic therapy. Perhaps then the technique eventually will become a routine adjunct to chemotherapy administration.

UR - http://www.scopus.com/inward/record.url?scp=0027355064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027355064&partnerID=8YFLogxK

M3 - Review article

SP - 167

EP - 175

JO - Important advances in oncology

JF - Important advances in oncology

SN - 0883-5896

ER -